Literature DB >> 9808486

Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

M E Falagas1, C Paya, R Ruthazer, A Badley, R Patel, R Wiesner, J Griffith, R Freeman, R Rohrer, B G Werner, D R Snydman.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) infection and disease has been found to be associated with decreased graft and patient survival among heart transplant recipients. We sought to explore the effect of CMV infection and disease on long-term survival in orthotopic liver transplant (OLT) recipients using a derivation and validation cohort.
METHODS: For derivation-validation modeling, we used data collected from two prospectively followed cohorts as the basis for multivariate analyses: 167 OLT recipients from the Boston Center for Liver Transplantation (the derivation set; median follow-up: 5.5 years, mortality: 40%) and an independent cohort of 294 OLT recipients from the Mayo Clinic (the validation set; median follow-up: 4.8 years, mortality: 27%).
RESULTS: Underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis, number of units of red blood cells administered during transplantation, and donor CMV seropositivity were the pre- and intratransplant variables independently associated (P<0.01) with decreased long-term survival in the derivation cohort. For variables collected up to 1 year after transplantation, the need for retransplan. tation, CMV pneumonia, invasive fungal disease, and underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis were independently associated (P<0.01) with decreased long-term survival in the derivation cohort. The magnitude of the relationship of each pre-, intra-, and posttransplant factor with survival, as measured by the relative risk, did not significantly differ between the derivation and validation cohorts. The derivation model, incorporating pre-, intra-, and posttransplant factors, had receiver operating characteristic areas of 73% and 74% for 5-year mortality in the derivation and validation cohorts, respectively.
CONCLUSIONS: Data from a derivation and an independent validation cohort demonstrate that CMV factors (reflected by either donor CMV seropositivity at transplantation, CMV pneumonia, or CMV disease within the first posttransplant year) are independently associated with decreased long-term survival in OLT recipients.

Entities:  

Mesh:

Year:  1998        PMID: 9808486     DOI: 10.1097/00007890-199810270-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients.

Authors:  Manisha Patel; Martha Stefanidou; Caroline B Long; Melissa J Fazzari; Lydia Tesfa; Marcela Del Rio; Jacqueline Lamour; Rosanna Ricafort; Rebecca P Madan; Betsy C Herold
Journal:  Pediatr Transplant       Date:  2011-07-18

3.  Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.

Authors:  S Pepperl; J Münster; M Mach; J R Harris; B Plachter
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.

Authors:  I Buerger; J Reefschlaeger; W Bender; P Eckenberg; A Popp; O Weber; S Graeper; H D Klenk; H Ruebsamen-Waigmann; S Hallenberger
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data.

Authors:  Daniel Teschner; Jana Knop; Christian Piehl; Sophia Junker; Oliver Witzke
Journal:  Infection       Date:  2022-05-28       Impact factor: 3.553

Review 6.  Cytomegalovirus infection in solid organ transplantation: economic implications.

Authors:  Ananya Das
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Addressing viral resistance through vaccines.

Authors:  Catherine Laughlin; Amanda Schleif; Carole A Heilman
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

8.  Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays.

Authors:  Angela M Caliendo; Kirsten St George; Jessica Allega; Arlene C Bullotta; Lisa Gilbane; Charles R Rinaldo
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 9.  Controlling cytomegalovirus: helping the immune system take the lead.

Authors:  Patrick J Hanley; Catherine M Bollard
Journal:  Viruses       Date:  2014-05-27       Impact factor: 5.048

Review 10.  Other inhibitors of viral enzymes and functions.

Authors:  H Zimmermann; G Hewlett; H Rübsamen-Waigmann
Journal:  Handb Exp Pharmacol       Date:  2009
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.